Burow Kristina 4

4 · Neumora Therapeutics, Inc. · Filed May 30, 2025

Form 4

Period: 2025-05-28

Director10% Owner

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−46,455→ 0 total
Exercise: $1.69Exp: 2033-09-14→ Common Stock (46,455 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+46,455→ 46,455 total
Exercise: $0.72Exp: 2033-09-14→ Common Stock (46,455 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+80,000→ 80,000 total
Exercise: $0.72Exp: 2035-05-27→ Common Stock (80,000 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+28,571→ 28,571 total
Exercise: $0.72Exp: 2034-06-13→ Common Stock (28,571 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−28,571→ 0 total
Exercise: $1.69Exp: 2034-06-13→ Common Stock (28,571 underlying)

Footnotes (5)

[F1]1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
[F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
[F3]100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
[F4]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
[F5]100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025.

Documents

1 file